Topical corticosteroid vehicle composition and implications for clinical practice.
Administration, Topical
Adrenal Cortex Hormones
/ administration & dosage
Biological Availability
Clinical Decision-Making
/ ethics
Cost-Benefit Analysis
Drug Compounding
/ methods
Drug Design
Humans
Pharmaceutical Vehicles
/ administration & dosage
Practice Patterns, Physicians'
/ standards
Safety
Skin
/ drug effects
Skin Diseases
/ drug therapy
Treatment Outcome
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
04
06
2020
revised:
05
08
2020
accepted:
07
08
2020
pubmed:
28
10
2020
medline:
13
10
2021
entrez:
27
10
2020
Statut:
ppublish
Résumé
This narrative review highlights the therapeutic significance of topical corticosteroid (TCS) vehicles and provides subsequent guidance to improve clinical and research outcomes. A greater understanding of the relationship between the topical vehicle, corticosteroid and skin is needed to ensure safer, more effective treatment for patients. Topical vehicles are not inert and can affect TCS bioavailability, due to the ability of their composition to positively or negatively influence skin status and change the physiochemical characteristics of an inherent corticosteroid. However, this principle is not commonly understood, and has contributed to inconsistencies in potency classification systems. This review provides an insight into the research methods and standardization needed to determine TCS product bioavailability. It identifies formulation components responsible for vehicle composition that underpin the quality, stability, compounding and functionalities of vehicle ingredients. This helps to contextualize how topical vehicles can be responsible for clinically significant effects, and how their composition gives products unique properties. In turn, this facilitates a more in-depth understanding of which resources offer information to inform the best selection of TCS products and why products should be prescribed by brand or manufacturer. This review will better equip clinicians and formulary teams to appraise products. It will also inform prescribing of Specials and why products should not be manipulated. The recommendations, accompanied by patient perspectives on using TCS products, assist clinical decision-making. They also identify the need for research into concomitant application of TCS products with other topical therapies.
Substances chimiques
Adrenal Cortex Hormones
0
Pharmaceutical Vehicles
0
Types de publication
Comparative Study
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
259-269Informations de copyright
© 2020 British Association of Dermatologists.
Références
Brockow K, Mortz C. Global atlas of skin allergy. Zurich: European Academy of Allergy and Clinical Immunology. 2019; 220-3. Available at: https://www.eaaci.org/images/Atlas/Global_Atlas_IV_v1.pdf (accessed 12 January 2020).
Surber C, Dragicevic N, Kottner J. Skin care products for healthy and diseased skin. Curr Probl Dermatol 2018; 54: 183-200.
Ersser S, Maguire S, Nicol N et al. Best practice in emollient therapy. A statement for healthcare professionals. Dermatolog Nurs 2012; 11: 60-9.
Berndt U, Wigger-Alberti W, Gabard B, Elsner P. Efficacy of a barrier cream and its vehicle as protective measures against occupational irritant contact dermatitis. Contact Dermatitis 2000; 42: 77-80.
Bayer plc. Summary of product characteristics (Diprobase cream). 2017. Available at: https://www.medicines.org.uk/emc/product/3503/smpc (accessed 15 March 2020).
Merck Sharp & Dohme Limited. Summary of product characteristics (Diprosone cream). 2019. Available at: https://www.medicines.org.uk/emc/product/6405/smpc (accessed 15 March 2020).
Diomed Developments Limited. Summary of product characteristics (Doublebase gel). 2019. Available at: https://www.medicines.org.uk/emc/product/13/smpc (accessed 15 March 2020).
Surber C, Knie U. Metamorphosis of vehicles: mechanisms and opportunities. Curr Probl Dermatol 2018; 54: 152-65.
Lippold B, Schneeman H. The influence of vehicles on the local bioavailability of betamethasone-17-benzoate from solution and suspension type ointments. Int J Pharm 1984; 22: 31-43.
Danby S, Chalmers J, Brown K et al. A functional mechanistic study of the effect of emollients on the structure and function of the skin barrier. Br J Dermatol 2016; 175: 1011-19.
Halling-Overgaard AS, Kezic S, Jakasa I et al. Skin absorption through atopic dermatitis skin: a systematic review. Br J Dermatol 2017; 177: 84-106.
Zsikó S, Csányi E, Kovács A et al. Methods to evaluate skin penetration in vitro. Sci Pharm 2019; 87: 19. Available at; https://www.mdpi.com/2218-0532/87/3/19 (accessed 27 November 2019).
Jakasa I, de Jongh C, Verberk M et al. Percutaneous penetration of sodium lauryl sulphate is increased in uninvolved skin of patients with atopic dermatitis compared with control subjects. Br J Dermatol 2006; 155: 104-9.
European Medicines Agency. Clinical investigation of corticosteroids intended for use on the skin. 1987. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/clinical-investigation-corticosteroids-intended-use-skin_en.pdf (accessed 27 February 2020).
European Medicines Agency. Draft guideline on quality and equivalence of topical products. London: European Medicines Agency; 2018. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-equivalence-topical-products_en.pdf (accessed 27 February 2020).
Schadt CR, Jackson SM. Glucocorticosteroids. In: Dermatology, 4th edn. (Bolognia J, Schaffer J, Cerroni L, Philadelphia, PA: ed). Elsevier Limited, 2018; 2186-99.
American Society of Health-System Pharmacists. Topical corticosteroids general statement. 2019. Available at: https://www.medicinescomplete.com/#/content/ahfs/a382909 (accessed 15 January 2020).
Gual A, Pau-Charles I, Abeck DA. Topical corticosteroids in dermatology: from chemical development to galenic innovation and therapeutic trends. J Clin Exp Dermatol Res 2015; 6: 2-5.
Hepburn D, Aeling J, Weston W. A reappraisal of topical steroid potency. Pediatr Int 1996; 13: 239-45.
Stoughton R. The vasoconstrictor assay in bioequivalence testing: practical concerns and recent developments. Int J Dermatol 1992; 31: 26-8.
United States Department of Health and Human Service, Food and Drug Administration. Centre for drug evaluation and research, guidance for industry. 1997. Available at: https://www.fda.gov/media/70931/download (accessed 17 November 2020).
British National Formulary Editorial Team. Topical corticosteroids. Treatment summary, 2019. Available at: https://bnf.nice.org.uk/treatment-summary/topical-corticosteroids.html (accessed 15 July 2019).
Norwegian Institute of Public Health. D07 corticosteroids dermatological preparations. WHO - ATC/DDD Index. 2019. Available at: https://www.whocc.no/atc_ddd_index/?code=D07AA&showdescription=no (accessed 13 June 2020).
World Health Organization. WHO model prescribing information: drugs used in skin diseases: annex: classification of topical corticosteroids. 2019. Available at: https://apps.who.int/iris/bitstream/handle/10665/41975/9241401060.pdf? (accessed 8 June 2019).
Medicines and Healthcare products Regulatory Agency. Final public assessment report, scientific discussion, Enstilar 50 µg/g + 0.5 mg/g cutaneous foam (calcipotriol monohydrate + betamethasone dipropionate). 2017. Available at: https://mri.cts-mrp.eu/Human/Downloads/DK_H_2478_001_PAR.pdf (accessed 24 January 2020).
Beattie P, Lewis-Jones M. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis. Clin Exp Dermatol 2003; 28: 549-53.
Teasdale E, Muller I, Sivyer K et al. Views and experiences of managing eczema: systematic review and thematic synthesis of qualitative studies. Br J Dermatol 2020.https://doi.org/10.1111/bjd.19299
Oakley R, Lawton S. Views on unwanted effects of leave-on emollients and experiences surrounding their incidence. Dermatolog Nurs 2016; 15: 38-43. Available at: http://eprints.nottingham.ac.uk/40443/1/DN%20Article.pdf (accessed 23 March 2020).
Antonijević MD, Owusu-Ware S, Sanchon-Lopez B. Emollient product design: objective measurements of formulation structure, texture and performance, and subjective assessments of user acceptability. Clin Exp Dermatol 2018; 43: 423-9.
PrescQIPP Community Interest Company. Dermatology specials (SPOT-List). 2017. Available at: https://www.prescqipp.info/media/1284/b168-dermatology-specials-spot-list-20.pdf (accessed 5 January 2020).
National Health Service Business Authority. Part VIIIB - Arrangements for payment for specials and imported unlicensed medicines. Available at: http://www.drugtariff.nhsbsa.nhs.uk/#/00770298-DC/DC00769722/Part%20VIIIB%20-%20Arrangements%20for%20payment%20for%20Specials%20and%20Imported%20Unlicensed%20Medicines (accessed 16 January 2020).
Buckley D, Root T, Bath S. Specials recommended by the British Association of Dermatologists for skin disease. 2018. Available at: http://www.bad.org.uk/shared/getfile.ashx?itemtype=document&id=6248 (accessed 27 December 2019).
Pharmaceutical Excipients Editorial Group. Pharmaceutical Excipients database. 2020. Available at: https://www.medicinescomplete.com (accessed 5 January 2020).
Boralevi F, Saint Aroman M, Delarue A et al. Long-term emollient therapy improves xerosis in children with atopic dermatitis. J Eur Acad Dermatol Venereol 2014; 28: 1456-62.
American Society of Health-System Pharmacists. Urea (topical). 2019. Available at: https://www.medicinescomplete.com/#/content/ahfs/a382436?hspl=Urea.
Gibson J, Darley C, Kirsch J et al. The dilution of proprietary corticosteroid ointments - an attempt to evaluate relative clinical potencies. Br J Dermatol 1982; 106: 445-8.
Pham Q, Björklund S, Engblom J et al. Chemical penetration enhancers in stratum corneum - relation between molecular effects and barrier function. J Control Release 2016; 232: 175-87.
Lane M. Skin penetration enhancers. Int J Pharm 2013; 447: 12-21.
Patzelt A, Lademann J, Richter H et al. In vivo investigations on the penetration of various oils and their influence on the skin barrier. Skin Res Technol 2012; 18: 364-9.